EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, Yael C Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross I Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac und 25 weitere

New England Journal of Medicine · 08.05.2025 · 392 (18) · 1777-1788

DOI: 10.1056/nejmoa2409029 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.05.2025. Verfasst von Meletios A Dimopoulos und 36 weiteren Autor:innen. Beteiligte Einrichtung: Alexandra General Hospital, National and Kapodistrian University of Athens, Athens. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents, Multiple Myeloma, Smoldering Multiple Myeloma. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Janssen Research & Development, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved. METHODS: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring. Treatment was continued for 39 cycles, for 36 months, or until confirmation of disease progression, whichever occurred first. The primary end point was progression-free survival; progression to active multiple myeloma was assessed by an independent review committee in accordance with International Myeloma Working Group diagnostic criteria. RESULTS: Among the 390 enrolled patients, 194 were assigned to the daratumumab group and 196 to the active-monitoring group. With a median follow-up of 65.2 months, the risk of disease progression or death was 51% lower with daratumumab than with active monitoring (hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.67; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntineoplastic AgentsMultiple MyelomaSmoldering Multiple MyelomaWatchful WaitingAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease ProgressionInjections, SubcutaneousKaplan-Meier EstimateProgression-Free Survival

Substanzen

Antibodies, MonoclonalAntineoplastic Agentsdaratumumab

Autor:innen und Institutionen

  • Alexandra General Hospital, National and Kapodistrian University of Athens, Athens.
  • Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC.
  • Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo.
  • Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel.
  • Clínica Medica São Germano, São Paulo.
  • Cross Cancer Institute, University of Alberta, Edmonton, Canada.

Förderung

  • Janssen Research & Development, LLC

Zitieren

APA

Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., Levin, M. D., Beksac, M., Stockerl-Goldstein, K., Oriol, A., Mikala, G., Garate, G., Theunissen, K., Spicka, I., Mylin, A. K., …, & AQUILA Investigators (2025). Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 392(18), 1777-1788. https://doi.org/10.1056/nejmoa2409029

Vancouver

Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 2025;392(18):1777-1788. doi:10.1056/nejmoa2409029

BibTeX
@article{Dimopoulos2025,
  author = {Dimopoulos, Meletios A and Voorhees, Peter M and Schjesvold, Fredrik and Cohen, Yael C and Hungria, Vania and Sandhu, Irwindeep and Lindsay, Jindriska and Baker, Ross I and Suzuki, Kenshi and Kosugi, Hiroshi and Levin, Mark-David and Beksac, Meral and Stockerl-Goldstein, Keith and Oriol, Albert and Mikala, Gabor and Garate, Gonzalo and Theunissen, Koen and Spicka, Ivan and Mylin, Anne K and Bringhen, Sara and Uttervall, Katarina and Pula, Bartosz and Medvedova, Eva and Cowan, Andrew J and Moreau, Philippe and Mateos, Maria-Victoria and Goldschmidt, Hartmut and Ahmadi, Tahamtan and Sha, Linlin and Cortoos, Annelore and Katz, Eva G and Rousseau, Els and Li, Liang and Dennis, Robyn M and Carson, Robin and Rajkumar, S Vincent and AQUILA Investigators, AQUILA Investigators},
  title = {Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {18},
  pages = {1777--1788},
  doi = {10.1056/nejmoa2409029}
}
Kostenlos starten →